The United States Patent and Trademark Office (USPTO) has issued a design patent (USD1120291S1) to Novo Nordisk A/S for a specific pill design. This patent, filed on May 30, 2024, and granted on March 24, 2026, pertains to the aesthetic appearance of the pill, not its functional composition or therapeutic effect.

This is a grant of intellectual property protection for a design. While it does not impose new compliance obligations on other entities, it signifies a proprietary design for Novo Nordisk's products. Companies in the pharmaceutical sector should be aware of this patent as it relates to product design and potential future market exclusivity for products incorporating this design.